Back to Stakeholders
Categories
1 domain / 2 areas / 1 specialization
Cessatech A/S
Data updated
Denmark
1 Trial
Cessatech A/S is a Copenhagen-based paediatric biotech developing CT001, a first-in-class intranasal ketamine/sufentanil combination analgesic for acute pain in children aged 1–17, with an EMA Marketing Authorisation Application submitted in 2025 and approval expected in 2026.
Academic Research
0 papersPublished Papers
0
Trial Involvement
1
Distinct Focus Topics
0
Latest Publication
Unknown
Quick Facts
- Type
- Public Biotech
- HQ
- Denmark
- Website
- Visit